Dental Medical Center, Hainan, Affiliated Hospital of Hainan Medical University (Hainan General Hospital), Haikou, Hainan, China.
State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, China.
Cell Prolif. 2024 Aug;57(8):e13637. doi: 10.1111/cpr.13637. Epub 2024 Apr 26.
Oral squamous cell carcinoma (OSCC), a type of malignant tumour that primarily occurs in the oral mucosa, has drawn considerable attention owing to its aggressive growth and potentially high metastatic rate. Surgical resection is the primary treatment method for OSCC and is typically combined with radiation therapy and chemotherapy. microRNA-149-3p (miR-149) is a negative regulator of the Pi3k/Akt pathway and can effectively inhibit the proliferation of tumour cells. However, the application of miR-149 is limited owing to its relatively low efficiency of cellular uptake and poor stability when used alone. To overcome these challenges, this study adopted a novel nucleic acid nanostructured material, tetrahedral framework nucleic acids (tFNAs). The use of tFNAs as carriers to assemble the T-miR-149 complex reduced the expression of Pi3k and Akt involved in tumorigenesis and alterations in proteins related to cell apoptosis. The results indicated that the bionic drug delivery system has an effective tumour suppressive effect on OSCC in mice, revealing its potential clinical value in the treatment of OSCC.
口腔鳞状细胞癌(OSCC)是一种主要发生在口腔黏膜的恶性肿瘤,由于其生长迅速且具有潜在的高转移率,因此引起了广泛关注。手术切除是 OSCC 的主要治疗方法,通常与放疗和化疗相结合。微小 RNA-149-3p(miR-149)是 Pi3k/Akt 通路的负调节剂,可有效抑制肿瘤细胞的增殖。然而,由于其细胞摄取效率相对较低且单独使用时稳定性较差,miR-149 的应用受到限制。为了克服这些挑战,本研究采用了一种新型核酸纳米结构材料,四面体框架核酸(tFNA)。使用 tFNA 作为载体组装 T-miR-149 复合物,降低了与肿瘤发生相关的 Pi3k 和 Akt 的表达以及与细胞凋亡相关的蛋白的改变。结果表明,仿生药物递送系统对小鼠的 OSCC 具有有效的肿瘤抑制作用,揭示了其在治疗 OSCC 方面的潜在临床价值。